Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers.
The antirhinovirus agent chalcone Ro 09-0410 was tested in double-blind place-controlled volunteer trials for its protective efficacy against experimental rhinovirus infection. Fifty volunteers received either drug (26 volunteers) or placebo (24 volunteers) both before and after challenge with 20-40 tissue culture infecting dose (TCID50) of human rhinovirus 2 (RV2). There was no evidence that medication significantly reduced the incidence of infection or illness, indeed there was some increase in the nasal secretion produced.
Al-Nakib
W
W
MRC Common Cold Unit, Harvard Hospital, Salisbury, Wiltshire, U.K.
Higgins
P G
PG
Barrow
I
I
Tyrrell
D A
DA
Lenox-Smith
I
I
Ishitsuka
H
H
D000281:Administration, Intranasal; D000998:Antiviral Agents / Q000008:administration & dosage*; D002599:Chalcone / Q000008:administration & dosage* / Q000031:analogs & derivatives; D047188:Chalcones; D002986:Clinical Trials as Topic; D003139:Common Cold / Q000517:prevention & control*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011427:Propiophenones / Q000008:administration & dosage*
D000998:Antiviral Agents; D047188:Chalcones; D011427:Propiophenones; D002599:Chalcone; C036425:Ro 09-0410